Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies

May 4, 2017 8:24 AM EDT
Get Alerts BPMC Hot Sheet
Price: $44.97 +5.64%

Rating Summary:
    16 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 13 | New: 33
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Jefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.

"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for BLU-285 in GIST as soon as 1H17, we see opportunity for further upside despite recent run-up in share price," analyst Carmen Augustine said.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co